ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

TIPS Effectively Treats Refractory Hepatic Hydrothorax: A Multi-Center U.S. Retrospective Study of 1,260 Patients

M. German1, A. Lee1, A. Hristov1, A. Said1, J. Boike2, J. Ge3, N. Jest4, G. Morelli4, K. Kolli3, J. Lai3, A. Desai5, S. Junna6, B. Pokhrel6, T. Couri7, S. Paul7, C. Frenette8, N. Christian-Miller8, E. Verna9, U. Rahim10, A. Goel10, A. Das2, S. Pine2, D. Gregory2, L. VanWagner2, E. Spengler1

1University of Wisconsin, Madison, WI, 2Northwestern University, Chicago, IL, 3University of California, San Francisco, San Francisco, CA, 4University of Florida, Gainesville, FL, 5University of Indiana, Indianapolis, IN, 6University of Arizona, Tucson, AZ, 7University of Chicago, Chicago, IL, 8Scripps Clinic, San Diego, CA, 9Columbia University, New York, NY, 10Stanford University, Palo Alto, CA

Meeting: 2019 American Transplant Congress

Abstract number: 570

Keywords: Liver cirrhosis, Quality of life

Session Information

Session Name: Concurrent Session: Liver: Recipient Selection

Session Type: Concurrent Session

Date: Tuesday, June 4, 2019

Session Time: 4:30pm-6:00pm

 Presentation Time: 5:42pm-5:54pm

Location: Room 312

*Purpose: Hepatic hydrothorax (HHT) occurs in 5-10% of patients with cirrhosis. Current literature on the use of transjugular intrahepatic portosystemic shunt (TIPS) in the treatment of HHT is limited to small retrospective studies and case series. We aimed to evaluate the efficacy of TIPS in the setting of HHT in a large, multi-center cohort.

*Methods: A multi-center, retrospective cohort study was conducted of patients with cirrhosis who underwent TIPS between 2010-2015 across 9 tertiary care centers as part of the Advancing Liver Therapeutic Approaches (ALTA) Consortium. Inclusion criteria were: age >18 years (y) and cirrhosis complications as indication for TIPS.

*Results: Of 1,260 TIPS recipients, 132 (11%) received a TIPS for HHT, of which 54 (41%) had refractory ascites as a secondary indication. Most (71%) HHTs were right-sided. Median age was 58y, 50% were male, 70% Caucasian, and 30% Hispanic. Liver disease etiologies were HCV (36%), alcohol (30%), and non-alcoholic fatty liver disease (21%). Pre-TIPS median MELD-Na for the HHT group was 21 (range 7-32), compared to the cohort median MELD-Na of 18 (range 6 – 45). 110 (83%) patients required a thoracentesis (clinically significant [cs]-HHT) within 12 months pre-TIPS, with a median of 2 (range 1-25) procedures. 83 (75%) patients who required at least one thoracentesis pre-TIPS had complete resolution of cs-HHT at 3 months post-TIPS. In those patients who had cs-HHT and clinically significant ascites (requiring at least 1 paracentesis) before TIPS, 78% (47/60) had complete resolution of cs-HHT at 3 months vs 76% (38/50) in those without clinically significant ascites. In 1y following TIPS, only 17 (13%) patients were able to discontinue diuretics. Four patients (3%) required a VATS procedure post-TIPS. Overall survival was comparable between the HHT cohort and overall cohort: 88% vs 86% at 30d, 78% vs 78% at 90d and 61% vs 65% at 1y, respectively. Similarly, TFS was also comparable: 76% vs 80% at 30d, 66% vs 69% at 90d, and 42% vs 53% at 1y, respectively.

*Conclusions: In the largest, multi-center, retrospective cohort of TIPS recipients in the US, we note that TIPS is a safe and effective method of treating HHT in the absence or presence of ascites. A majority (75%) of patients had complete resolution of clinically significant HHT at 3 months post-TIPS. Overall and TFS were similar between those patients receiving TIPS for an indication of HHT versus other indications.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

German M, Lee A, Hristov A, Said A, Boike J, Ge J, Jest N, Morelli G, Kolli K, Lai J, Desai A, Junna S, Pokhrel B, Couri T, Paul S, Frenette C, Christian-Miller N, Verna E, Rahim U, Goel A, Das A, Pine S, Gregory D, VanWagner L, Spengler E. TIPS Effectively Treats Refractory Hepatic Hydrothorax: A Multi-Center U.S. Retrospective Study of 1,260 Patients [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/tips-effectively-treats-refractory-hepatic-hydrothorax-a-multi-center-u-s-retrospective-study-of-1260-patients/. Accessed May 9, 2025.

« Back to 2019 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences